06922 CRYOFOCUS-B
- 7.780
- -0.020-0.26%
CRYOFOCUS-B News
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
康灃生物-B：2023年年報
Kang Feng Bio-B (06922.HK): The Stock Exchange granted listing approval to implement full circulation of H shares
Gelonghui, April 3 | Kang Feng Bio-B (06922.HK) announced that the company has applied to the Stock Exchange Listing Committee to approve 29,341,981 H shares of the company, that is, the maximum number of unlisted shares of the company to be converted, listed and traded under the conversion and listing. The Company is pleased to announce that on April 3, 2024, the Stock Exchange has granted listing approval, which is subject to all other conditions for conversion and listing before it can be implemented.
Kang Feng Bio-B (06922) announced 2023 results. Loss attributable to parent company owners of 97.486 million yuan narrowed 13.13% year-on-year
Kang Feng Bio-B (06922) announced its 2023 results, with revenue of about 40.95 million yuan, an increase of 50.8 over the previous year...
CRYOFOCUS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Kang Feng Bio-B (06922.HK) plans to hold a board meeting on March 27 to approve the annual results
Gelonghui, March 13 | Kang Feng Bio-B (06922.HK) issued an announcement. The board of directors is pleased to hold a board meeting on March 27, 2024 (Wednesday) to review and approve the Group's annual results and announcements for the year ended 31 December 2023, as well as to consider the payment of a final dividend (if any).
康灃生物-B：董事會會議日期
Kang Feng Bio-B (06922): The China Securities Regulatory Commission issued a filing notice on the company's application for full circulation of H shares
Kang Feng Bio-B (06922) issued an announcement. The company recently supervised the implementation of the full circulation of the company's H shares to China Securities...
Cryofocus Medtech Gets Marketing Approval in China for Cryoadhesion System
China's National Medical Products Administration granted marketing authorization to Cryofocus Medtech (Shanghai)'s (HKG:6922) Cryoadhesion system on Jan. 9, 2024. The authorization comes after the reg
Kang Feng Bio-B (06922.HK): The one-time use of a frozen probe in the cryoadhesion treatment system obtained approval from the State Drug Administration
Gelonghui, January 15, 丨 Kang Feng Bio-B (06922.HK) issued an announcement. Following approval from the State Drug Administration (“State Drug Administration”) for the cryotherapy equipment supporting the cryoadhesion treatment system on December 22, 2023, other components of the cryoadhesion treatment system (that is, single-use cryoprobes) have obtained approval from the State Drug Administration on January 9, 2024. After obtaining all such approvals from the State Drug Administration, the Group's cryoadhesion treatment system has been approved for marketing by the State Drug Administration. The cryoadhesion treatment system uses subcritical refrigeration technology and pressure control
Cryofocus Medtech Secures Manufacturing Certification
Cryofocus Medtech (HKG:6922) secured a Good Manufacturing Practice certification from the Shanghai Medical Products Administration. The certification is a necessary step in the production and commerci
Announcement selection: Great Wall Motor's sales last month increased by more than 40% year on year; China Railway Construction recently won a bid of 73.298 billion yuan for a major project
C&D International Group: The cumulative contract sales amount in 2023 was about 137.96 billion yuan, an increase of 13.5% over the previous year; Kingsley Biotech: Legend Biotech and Novartis completed a global licensing agreement.
China's Medical Products Administrator Approves Cryofocus Medtech's Cryotherapy Equipment
China's medical products administrator approved Cryofocus Medtech (Shanghai)'s (HKG:6922) accompanying cryotherapy equipment for its cryoadhesion system, a Wednesday filing said. The equipment aims to
Featured announcements | NIO announces completion of US$2.2 billion strategic equity investment; Tencent spent HK$1 billion to repurchase shares
Qingdao Port: It is expected to complete a cargo throughput of 660 million tons in 2023, an increase of 5.8% over the previous year; China Southern Airlines Co., Ltd. plans to increase the capital of Sichuan Airlines by 4.68 billion yuan.
Guoyuan International: Target price of HK$28 for Kang Feng Biotech (06922) “buy” rating
Leading cryointerventional devices, with outstanding clinical efficacy, are about to usher in high growth
Kang Feng Bio-B (6922.HK): Outstanding clinical efficacy of leading cryointerventional devices is about to usher in high growth
Investment points The cryointerventional industry is growing rapidly, and the company is a leader in the field of cryointervention. Currently, commercial products are bladder cancer cryoablation systems. The pipeline includes vascular cryointerventional systems and natural cavity cryointerventional systems, which are used to treat atrial fibrillation and high blood pressure, respectively; slow
Cryofocus Medtech's AF Cryoablation System Wins Marketing Approval in China
China's National Medical Products Administration has approved the two remaining key components of Cryofocus Medtech (Shanghai)'s (HKG:6922) atrial fibrillation (AF) cryoablation system. With that, the
Kangfeng Bio-B (06922): One-off use of cardiac cryoablation systems with intracardiac measurement catheters and adjustable bending guide tubes obtained approval from the State Drug Administration
Kangfeng Bio-B (06922) issued an announcement. Following the two main components of the cardiac cryoablation system, namely the cryoablation system...
Chinese Regulator Green Lights 2 Components of Cryofocus Medtech's Atrial Fibrillation System
The National Medical Products Administration of China approved two key components of Cryofocus Medtech (Shanghai)'s (HKG:6922) atrial fibrillation cryoablation system on Monday.
Kangfeng Bio-B (06922): The main components of the cardiac cryoablation system have been approved by the State Drug Administration
According to the Zhitong Finance App, Kangfeng Biotech B (06922) announced that on December 4, 2023, the two main components of its cardiac cryoablation system (cardiac cryoablation system), namely cryoablation equipment and a balloon cryoablation catheter (previously known as atrial fibrillation cryoablation catheter) (balloon type cryoablation catheter), have received approval from the State Drug Administration. Freeze-ablation equipment mainly includes a refrigeration device and a control system. Its main function is to deliver refrigerant to a balloon-type cryoablation catheter. The balloon type cryoablation catheter is a flexible balloon catheter. It mainly includes three components, namely equipment connection parts
Analysis
Price Target
No Data
